mianserin has been researched along with Sleep Initiation and Maintenance Disorders in 43 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study mirtazapine rapidly improved nausea, sleep disturbance, pain and quality of life, as well as depression in cancer patients." | 9.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 9.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 7.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "The clinical response of our patients underscores the usefulness of mirtazapine in the treatment of the comorbid symptoms of weight loss, insomnia, and anxiety." | 7.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "Mirtazapine is an antidepressant that has a receptor-binding profile that may suit it for use in controlling the nausea and insomnia of highly emetic cancer chemotherapy." | 7.71 | Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. ( Kast, RE, 2001) |
| " In addition, a dose-response effect was seen with Org 3770, 15 mg seeming optimal." | 6.66 | A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. ( Bettum, V; Dunbar, GC; Jørgensen, J; Steffensen, K; Sørensen, M; Viby-Mogensen, J, 1985) |
| "In the present study mirtazapine rapidly improved nausea, sleep disturbance, pain and quality of life, as well as depression in cancer patients." | 5.13 | Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. ( Kim, JM; Kim, KM; Kim, KS; Kim, SW; Kim, YC; Shin, IS; Yang, SJ; Yoon, JS, 2008) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 5.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| "The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs)." | 5.09 | A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. ( Guenin, KD; Kohn, AE; McDougle, CJ; Posey, DJ; Swiezy, NB, 2001) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 3.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "The clinical response of our patients underscores the usefulness of mirtazapine in the treatment of the comorbid symptoms of weight loss, insomnia, and anxiety." | 3.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "Mirtazapine is an antidepressant that has a receptor-binding profile that may suit it for use in controlling the nausea and insomnia of highly emetic cancer chemotherapy." | 3.71 | Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. ( Kast, RE, 2001) |
| "Patients aged 18 to 65 years with primary insomnia were randomized to receive placebo or 1." | 2.82 | A Phase 2 Randomized Dose-Finding Study With Esmirtazapine in Patients With Primary Insomnia. ( IJzerman-Boon, P; Ivgy-May, N; Roth, T; Ruwe, F; Zammit, G, 2016) |
| "Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| " Measures to assess the potential adverse effects of treatment included morning alertness, daytime function/napping, and rebound insomnia during a single-blind placebo run-out week after treatment ended." | 2.80 | Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial. ( Ivgy-May, N; Roth, T; Ruwe, F; Walsh, J, 2015) |
| " Overall, 35-42% of esmirtazapine-treated patients had adverse events (AEs) versus 29% in the placebo group." | 2.80 | Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. ( Ivgy-May, N; Krystal, A; Roth, T; Ruwe, F, 2015) |
| " Mirtazapine in fixed and ascending nocturnal dosing regimens was found to facilitate sleep, but it does not generally reduce daytime alertness." | 2.69 | Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. ( O'Hanlon, JF; Radhakishun, FS; Roes, KC; van den Bos, J; van der Heijden, BC, 2000) |
| " In addition, a dose-response effect was seen with Org 3770, 15 mg seeming optimal." | 2.66 | A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. ( Bettum, V; Dunbar, GC; Jørgensen, J; Steffensen, K; Sørensen, M; Viby-Mogensen, J, 1985) |
| "Insomnia disorder is a subjective condition of unsatisfactory sleep (e." | 2.58 | Antidepressants for insomnia in adults. ( Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S, 2018) |
| "Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs." | 2.47 | [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| "Mirtazapine is an effective antidepressant with unique and special mechanism of action characterized by high response and remission rates, relatively early onest of action and favourable side-effect profile." | 2.45 | [Mirtazapine--pharmacologic action and clinical advantages]. ( Purebl, G; Rihmer, Z, 2009) |
| "Whether insomnia is a precursor, symptom, residual symptom, or side effect of depression or its treatment, clinicians must give serious attention to and attempt to resolve sleep disturbances because of the risk of depression onset, worsening of depressive symptoms, and relapse of depression after response to antidepressant treatment." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| " The rates for individual side effects with the serotonin selective reuptake inhibitors, nefazodone, and venlafaxine are presented and compared with the adverse event experience for mirtazapine." | 2.40 | Safety and tolerability of the new antidepressants. ( Nelson, JC, 1997) |
| "Insomnia is a particularly frequent complaint, and it is reported by more than 90% of depressed patients." | 2.40 | Antidepressant treatment of the depressed patient with insomnia. ( Thase, ME, 1999) |
| "Acquired neuromyotonia manifests clinically in cramps, fasciculations, and stiffness." | 1.42 | Neuromyotonia with polyneuropathy, prominent psychoorganic syndrome, insomnia, and suicidal behavior without antibodies: a case report. ( Ehler, E; Meleková, A, 2015) |
| "In 3,455 MDD outpatients with insomnia after treatment, the reduction of sleep latency (P < 0." | 1.40 | Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder. ( Hao, W; Li, L; Li, Z; Wang, D, 2014) |
| "Mirtazapine is a commonly prescribed antidepressant drug, which is also metabolized through and may modulate the CYP4502D6 pathway leading to altered metabolism of propafenone and possible adverse effects." | 1.40 | Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. ( Aryal, SR; Khan, MA; Rajpurohit, N; Stys, AT; Stys, TP, 2014) |
| "Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA." | 1.34 | Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. ( Choi, MJ; Hahn, SW; Kang, RH; Lee, MS; Paik, JW, 2007) |
| "Six patients meeting criteria for major depressive disorder and scoring > or =4 on the three Hamilton Depression Rating Scale sleep items were studied." | 1.31 | Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. ( Bayles-Dazet, W; Gary, KA; Hayes, JB; MacDonald, MM; Sateia, MJ; Winokur, A, 2000) |
| "Although hepatolenticular degeneration is rare, it commonly presents with psychiatric symptoms." | 1.30 | Depression in hepatolenticular degeneration (Wilson's disease). ( Lyndon, B; Walter, G, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 23 (53.49) | 29.6817 |
| 2010's | 13 (30.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everitt, H | 1 |
| Baldwin, DS | 1 |
| Stuart, B | 1 |
| Lipinska, G | 1 |
| Mayers, A | 1 |
| Malizia, AL | 1 |
| Manson, CC | 1 |
| Wilson, S | 1 |
| Wang, D | 1 |
| Li, Z | 1 |
| Li, L | 1 |
| Hao, W | 1 |
| Rajpurohit, N | 1 |
| Aryal, SR | 1 |
| Khan, MA | 1 |
| Stys, AT | 1 |
| Stys, TP | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 1 |
| Luther, JF | 1 |
| Trivedi, MH | 1 |
| Rush, AJ | 1 |
| Ehler, E | 1 |
| Meleková, A | 1 |
| Ivgy-May, N | 3 |
| Roth, T | 3 |
| Ruwe, F | 3 |
| Walsh, J | 1 |
| Krystal, A | 1 |
| IJzerman-Boon, P | 1 |
| Zammit, G | 1 |
| Karsten, J | 1 |
| Hagenauw, LA | 1 |
| Kamphuis, J | 1 |
| Lancel, M | 1 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Dolev, Z | 1 |
| Wichniak, A | 1 |
| Wierzbicka, A | 1 |
| Clark, MS | 1 |
| Smith, PO | 1 |
| Jamieson, B | 1 |
| Uguz, F | 1 |
| Lewis, JD | 1 |
| Palomäki, H | 1 |
| Berg, A | 1 |
| Meririnne, E | 1 |
| Kaste, M | 1 |
| Lönnqvist, R | 1 |
| Lehtihalmes, M | 1 |
| Lönnqvist, J | 1 |
| Winokur, A | 2 |
| DeMartinis, NA | 1 |
| McNally, DP | 1 |
| Gary, EM | 1 |
| Cormier, JL | 1 |
| Gary, KA | 2 |
| Lawrence, RW | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Fava, M | 1 |
| Wingen, M | 1 |
| Bothmer, J | 1 |
| Langer, S | 1 |
| Ramaekers, JG | 1 |
| Shen, J | 1 |
| Chung, SA | 1 |
| Kayumov, L | 1 |
| Moller, H | 1 |
| Hossain, N | 1 |
| Wang, X | 1 |
| Deb, P | 1 |
| Sun, F | 1 |
| Huang, X | 1 |
| Novak, M | 1 |
| Appleton, D | 1 |
| Shapiro, CM | 1 |
| Adler, LA | 1 |
| Reingold, LS | 1 |
| Morrill, MS | 1 |
| Wilens, TE | 1 |
| Fusar-Poli, P | 1 |
| Matteo, L | 1 |
| Luca, de M | 1 |
| Politi, P | 1 |
| Cortesi, M | 1 |
| Carboni, V | 1 |
| Prospero-Garcia, KA | 1 |
| Torres-Ruiz, A | 1 |
| Ramirez-Bermudez, J | 1 |
| Velazquez-Moctezuma, J | 1 |
| Arana-Lechuga, Y | 1 |
| Teran-Perez, G | 1 |
| Tuya, AC | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Kim, YC | 1 |
| Kim, KS | 1 |
| Kim, KM | 1 |
| Yang, SJ | 1 |
| Yoon, JS | 1 |
| Kang, RH | 1 |
| Choi, MJ | 1 |
| Paik, JW | 1 |
| Hahn, SW | 1 |
| Lee, MS | 1 |
| Hoc, J | 1 |
| Nelson, JC | 1 |
| Walter, G | 1 |
| Lyndon, B | 1 |
| Thase, ME | 2 |
| Davis, J | 1 |
| Barkin, RL | 1 |
| Sateia, MJ | 1 |
| Hayes, JB | 1 |
| Bayles-Dazet, W | 1 |
| MacDonald, MM | 1 |
| Radhakishun, FS | 1 |
| van den Bos, J | 1 |
| van der Heijden, BC | 1 |
| Roes, KC | 1 |
| O'Hanlon, JF | 1 |
| Raji, MA | 1 |
| Brady, SR | 1 |
| Kast, RE | 1 |
| Posey, DJ | 1 |
| Guenin, KD | 1 |
| Kohn, AE | 1 |
| Swiezy, NB | 1 |
| McDougle, CJ | 1 |
| De Sousa, MP | 1 |
| Tropa, JR | 1 |
| Sørensen, M | 1 |
| Jørgensen, J | 1 |
| Viby-Mogensen, J | 1 |
| Bettum, V | 1 |
| Dunbar, GC | 1 |
| Steffensen, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00482612] | Phase 3 | 526 participants (Actual) | Interventional | 2006-12-07 | Completed | ||
| A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00506389] | Phase 3 | 419 participants (Actual) | Interventional | 2007-06-06 | Completed | ||
| Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea[NCT05303935] | Phase 2 | 15 participants (Actual) | Interventional | 2022-05-25 | Completed | ||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder[NCT00385437] | Phase 2 | 16 participants | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
SL was defined as the duration of time measured in minutes that it took a participant to fall asleep as recorded daily in the participant's sleep diary. SL values over the 14-day active treatment period were averaged for each participant, and average SL was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present were used in the analysis. (NCT00482612)
Timeframe: Day 1 to Day 15
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 1.5 mg | 48.93 |
| Esmirtazapine 3.0 mg | 52.02 |
| Esmirtazapine 4.5 mg | 50.80 |
| Placebo | 60.13 |
TST was defined as the total amount of time (measured in minutes) that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 14-day active treatment period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present was used in the analysis. (NCT00482612)
Timeframe: Day 1 to Day 15
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 1.5 mg | 382.14 |
| Esmirtazapine 3.0 mg | 382.77 |
| Esmirtazapine 4.5 mg | 394.83 |
| Placebo | 351.40 |
The total number of participants with an AE during the 14-day In-treatment Period was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00482612)
Timeframe: Day 1 to Day 15
| Intervention | Number of participants (Number) |
|---|---|
| Esmirtazapine 1.5 mg | 35 |
| Esmirtazapine 3.0 mg | 41 |
| Esmirtazapine 4.5 mg | 41 |
| Placebo | 28 |
The total number of participants discontinuing from study treatment due to experiencing an AE was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT00482612)
Timeframe: Day 1 to Day 15
| Intervention | Number of participants (Number) |
|---|---|
| Esmirtazapine 1.5 mg | 4 |
| Esmirtazapine 3.0 mg | 7 |
| Esmirtazapine 4.5 mg | 9 |
| Placebo | 0 |
LPS was defined as the time in minutes from lights out to the first 20 consecutive epochs scored as sleep as measured by PSG. LPS was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 28.7 |
| Esmirtazapine 4.5 mg | 26.1 |
| Placebo | 40.5 |
TST was defined as the total amount of time in minutes that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 6 week In-Treatment Period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were available was used in the analysis. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 384.6 |
| Esmirtazapine 4.5 mg | 384.6 |
| Placebo | 351.6 |
WASO was defined as the total objective time awake after the onset of persistent sleep until the end of the 8-hour sleep cycle period as measured by polysomnography (PSG). WASO was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 45.6 |
| Esmirtazapine 4.5 mg | 45.5 |
| Placebo | 76.1 |
8 reviews available for mianserin and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Antidepressants for insomnia in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Mianserin; Parox | 2018 |
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
[Mirtazapine--pharmacologic action and clinical advantages].
Topics: Adrenergic alpha-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Depress | 2009 |
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl | 2011 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
Safety and tolerability of the new antidepressants.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv | 1997 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Human | 1999 |
Treatment issues related to sleep and depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Humans; M | 2000 |
17 trials available for mianserin and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
Topics: Adult; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypno | 2015 |
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2015 |
A Phase 2 Randomized Dose-Finding Study With Esmirtazapine in Patients With Primary Insomnia.
Topics: Adult; Antidepressive Agents, Tricyclic; Cross-Over Studies; Double-Blind Method; Female; Humans; Ma | 2016 |
Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Cognition; Cross-Over Studies; Double-Blind Meth | 2017 |
Complaints of poststroke insomnia and its treatment with mianserin.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, | 2003 |
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord | 2003 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Automobile Driving; Circadian Rhythm; Citalopram; C | 2005 |
Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Drug Admin | 2006 |
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combinati | 2006 |
Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.
Topics: Adjustment Disorders; Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Depressiv | 2008 |
The clinical efficacy and side-effects of mianserin and nortriptyline in depressed out-patients: a double-blind randomized trial.
Topics: Adult; Aged; Ambulatory Care; Clinical Trials as Topic; Depression; Depressive Disorder; Dibenzazepi | 1982 |
Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.
Topics: Affect; Antidepressive Agents, Tricyclic; Attention; Depressive Disorder; Dose-Response Relationship | 2000 |
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Autist | 2001 |
Comparative study of the therapeutic and adverse effects of two antidepressants--dothiepin and mianserin.
Topics: Adjustment Disorders; Adult; Aged; Circadian Rhythm; Depressive Disorder; Dibenzazepines; Dibenzothi | 1986 |
A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery.
Topics: Adult; Anxiety; Blood Pressure; Diazepam; Dibenzazepines; Dose-Response Relationship, Drug; Double-B | 1985 |
18 other studies available for mianserin and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Ag | 2014 |
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Atrial Fibrillation; Bradycardia; Di | 2014 |
Neuromyotonia with polyneuropathy, prominent psychoorganic syndrome, insomnia, and suicidal behavior without antibodies: a case report.
Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Second-Generation; Electromyography; Huma | 2015 |
Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.
Topics: Antidepressive Agents, Tricyclic; Body Weight; Delayed-Action Preparations; Dose-Response Relationsh | 2011 |
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re | 2011 |
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E | 2013 |
Mirtazapine for PTSD nightmares.
Topics: Antidepressive Agents; Dreams; Humans; Mianserin; Mirtazapine; Refugees; Sleep Initiation and Mainte | 2002 |
Effect of mirtazapine versus fluoxetine on "sleep quality".
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug | 2004 |
[Motivational therapy can fail here. Sleep disorders in depressions].
Topics: Antidepressive Agents, Tricyclic; Arousal; Citalopram; Depressive Disorder, Major; Dose-Response Rel | 2004 |
Combination pharmacotherapy for adult ADHD.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 2006 |
Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; | 2007 |
The management of insomnia in the older adult.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Baths; Exercise; Humans; Hypnot | 2007 |
Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.
Topics: Antidepressive Agents, Tricyclic; Asian People; Case-Control Studies; Depressive Disorder, Major; Fe | 2007 |
Depression in hepatolenticular degeneration (Wilson's disease).
Topics: Adult; Antidepressive Agents, Tricyclic; Chelating Agents; Comorbidity; Depressive Disorder; Drug Th | 1997 |
Clinical pharmacology of mirtazapine: revisited.
Topics: Agranulocytosis; Antidepressive Agents, Tricyclic; Anxiety; Depression; Humans; Mianserin; Mirtazapi | 1999 |
Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive | 2000 |
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Comorbidity; Depressio | 2001 |
Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
Topics: Antidepressive Agents, Tricyclic; Antineoplastic Agents; Humans; Mianserin; Mirtazapine; Nausea; Sle | 2001 |